The pharmaceutical industry continues to be a hotbed of innovation, with activity driven by the evolution of new treatment paradigms, and the gravity of unmet needs, as well as the growing importance of technologies such as pharmacogenomics, digital therapeutics, and artificial intelligence. In the last three years alone, there have been over 633,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Innovation in Pharmaceuticals: Transcription factors for genetically modified cells. Buy the report here.
However, not all innovations are equal and nor do they follow a constant upward trend. Instead, their evolution takes the form of an S-shaped curve that reflects their typical lifecycle from early emergence to accelerating adoption, before finally stabilising and reaching maturity.
Identifying where a particular innovation is on this journey, especially those that are in the emerging and accelerating stages, is essential for understanding their current level of adoption and the likely future trajectory and impact they will have.
110 innovations will shape the pharmaceutical industry
According to GlobalData’s Technology Foresights, which plots the S-curve for the pharmaceutical industry using innovation intensity models built on over 756,000 patents, there are 110 innovation areas that will shape the future of the industry.
Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely. Adeno-associated virus vectors, alcohol dehydrogenase compositions, and antibody serum stabilisers are some of the accelerating innovation areas, where adoption has been steadily increasing. Among maturing innovation areas are anti-influenza antibody compositions and anti-interleukin-1, which are now well established in the industry.
Innovation S-curve for the pharmaceutical industry
Transcription factors for genetically modified cells is a key innovation area in the pharmaceutical industry
Transcription factors are proteins which control gene expression by controlling the rate of transcription of genetic information from DNA to RNA. Artificial transcription factors such as CRISPR-CAS9 are widely used to precisely regulate gene expression in various genetically modified cells.
GlobalData’s analysis also uncovers the companies at the forefront of each innovation area and assesses the potential reach and impact of their patenting activity across different applications and geographies. According to GlobalData, there are 40+ companies, spanning technology vendors, established pharmaceutical companies, and up-and-coming start-ups engaged in the development and application of transcription factors for genetically modified cells.
Key players in the transcription factors for genetically modified cells space – a disruptive innovation in the pharmaceutical industry
‘Application diversity’ measures the number of different applications identified for each relevant patent and broadly splits companies into either ‘niche’ or ‘diversified’ innovators.
‘Geographic reach’ refers to the number of different countries each relevant patent is registered in and reflects the breadth of geographic application intended, ranging from ‘global’ to ‘local’.
Patent volumes related to transcription factors for genetically modified cells
|Company||Total patents (2010 - 2021)||Premium intelligence on the world's largest companies|
|Fujifilm Holdings||162||Unlock company profile|
|I'rom Group||51||Unlock company profile|
|Allele Biotechnology and Pharmaceuticals||48||Unlock company profile|
|Ministry of Trade and Industry, Singapore||43||Unlock company profile|
|BioNTech||41||Unlock company profile|
|Johnson & Johnson||36||Unlock company profile|
|Genesis Technologies||34||Unlock company profile|
|Cellscript||33||Unlock company profile|
|BioLamina||33||Unlock company profile|
|Taiga Biotechnologies||29||Unlock company profile|
|Lonza Group||22||Unlock company profile|
|National Cancer Center||22||Unlock company profile|
|Children's Medical Center||20||Unlock company profile|
|F. Hoffmann-La Roche||20||Unlock company profile|
|Mesoblast||16||Unlock company profile|
|ReNeuron Group||15||Unlock company profile|
|Daiichi Sankyo||15||Unlock company profile|
|Mayo Clinic||14||Unlock company profile|
|New World Laboratories||13||Unlock company profile|
|TRON gGmbH||13||Unlock company profile|
|Kangstem Biotech||12||Unlock company profile|
|Bristol-Myers Squibb||12||Unlock company profile|
|Memorial Sloan Kettering Cancer Center||11||Unlock company profile|
|Stemlab||10||Unlock company profile|
|Touchlight Genetics||10||Unlock company profile|
|Mclean Hospital||10||Unlock company profile|
|Hong Guan||10||Unlock company profile|
|Scripps Health||10||Unlock company profile|
|Takara Holdings||10||Unlock company profile|
|City of Hope||8||Unlock company profile|
|Wellcome Trust||8||Unlock company profile|
|Green Cross Holdings||7||Unlock company profile|
|Max-Planck-Gesellschaft||7||Unlock company profile|
|Centre National de la Recherche Scientifique||7||Unlock company profile|
|LifeSci Index Partners||7||Unlock company profile|
|Orig3N||7||Unlock company profile|
|UAB Research Foundation||7||Unlock company profile|
|General Hospital||7||Unlock company profile|
|Cedars-Sinai Health System||6||Unlock company profile|
|Riken||6||Unlock company profile|
|ReproCELL||6||Unlock company profile|
|Novagenesis||5||Unlock company profile|
|Guangzhou Biocare Biotechnology||5||Unlock company profile|
Source: GlobalData Patent Analytics
I'rom Group is the leading patent holder for transcription factors for genetically modified cells. The company has filed several patents for the production of induced pluripotent stem cells by using transcription factors. The Company is also developing several other innovations using transcription factors to produce genetically modified cells.
In terms of application diversity, Kangstem Biotech is the top company, followed by Cellscript and Novagenesis. By means of geographic reach, New World Laboratories holds the top position. Stemlab, and Research and Touchlight Genetics stand in second and third positions, respectively.
To further understand the key themes and technologies disrupting the pharmaceutical industry, access GlobalData’s latest thematic research report on Pharmaceutical.